Tags

Type your tag names separated by a space and hit enter

[Treatment of dyslipidemia in clinical practice].
Orv Hetil. 2006 Mar 05; 147(9):389-94.OH

Abstract

The incidence of dyslipidemia is rising worldwide. Dyslipidemia combined with other factors represent the primary risk factors for the development of cardiovascular diseases. The National Cholesterol Education Program has recently updated the Adult Treatment Panel III guidelines and called for more intensive lipid lowering treatment, especially in patients at high risk for coronary heart disease. A statin and fibrate combination is a possible approach, moreover, niacin, particularly in combination with statins, might have a successful comeback. However, despite the existence of evidence-based treatment guidelines and effective antilipemic medications, recommended cardiovascular risk reduction rarely is achieved. This article summarises the mechanisms of action of available lipid lowering agents, their recommended dosing regiments and possible drug interactions.

Authors+Show Affiliations

Paragh G
Debreceni Egyetem, Orvos-es Egészségtudományi Centrum, Altalános Orvostudományi Kar, 1. Belgyógyászati Klinika.
Harangi M
No affiliation info available

MeSH

CholesterolCholesterol, DietaryCholesterol, HDLCholesterol, LDLCholesterol, VLDLClofibric AcidCytochrome P-450 Enzyme SystemDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsRisk AssessmentRisk FactorsTriglycerides

Pub Type(s)

English Abstract
Journal Article
Review

Language

hun

PubMed ID

16619956

Citation

Paragh, György, and Mariann Harangi. "[Treatment of Dyslipidemia in Clinical Practice]." Orvosi Hetilap, vol. 147, no. 9, 2006, pp. 389-94.
Paragh G, Harangi M. [Treatment of dyslipidemia in clinical practice]. Orv Hetil. 2006;147(9):389-94.
Paragh, G., & Harangi, M. (2006). [Treatment of dyslipidemia in clinical practice]. Orvosi Hetilap, 147(9), 389-94.
Paragh G, Harangi M. [Treatment of Dyslipidemia in Clinical Practice]. Orv Hetil. 2006 Mar 5;147(9):389-94. PubMed PMID: 16619956.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of dyslipidemia in clinical practice]. AU - Paragh,György, AU - Harangi,Mariann, PY - 2006/4/20/pubmed PY - 2006/5/10/medline PY - 2006/4/20/entrez SP - 389 EP - 94 JF - Orvosi hetilap JO - Orv Hetil VL - 147 IS - 9 N2 - The incidence of dyslipidemia is rising worldwide. Dyslipidemia combined with other factors represent the primary risk factors for the development of cardiovascular diseases. The National Cholesterol Education Program has recently updated the Adult Treatment Panel III guidelines and called for more intensive lipid lowering treatment, especially in patients at high risk for coronary heart disease. A statin and fibrate combination is a possible approach, moreover, niacin, particularly in combination with statins, might have a successful comeback. However, despite the existence of evidence-based treatment guidelines and effective antilipemic medications, recommended cardiovascular risk reduction rarely is achieved. This article summarises the mechanisms of action of available lipid lowering agents, their recommended dosing regiments and possible drug interactions. SN - 0030-6002 UR - https://www.unboundmedicine.com/medline/citation/16619956/[Treatment_of_dyslipidemia_in_clinical_practice]_ DB - PRIME DP - Unbound Medicine ER -